Welcome to our dedicated page for Precision Biosciences news (Ticker: DTIL), a resource for investors and traders seeking the latest updates and insights on Precision Biosciences stock.
Precision BioSciences, Inc. reports developments for a clinical-stage gene editing company using its proprietary ARCUS platform to develop in vivo therapies for diseases with high unmet need. Company news centers on PBGENE-HBV for chronic hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy, including clinical-program updates, regulatory clearances and designations, scientific-meeting presentations, and data from the ELIMINATE-B and FUNCTION-DMD studies.
Recurring updates also include quarterly financial results, cash runway commentary, business priorities, and equity-compensation grants under Nasdaq inducement-award rules. Precision describes ARCUS applications across gene elimination, excision, and insertion, with program-specific disclosures tied to viral DNA, cccDNA, defective-gene removal, and AAV delivery.
Precision BioSciences (Nasdaq: DTIL) will host an investor webcast on May 27, 2026, at 8:00 AM EDT. The event will feature Hepatitis B experts and company management discussing new biopsy and clinical data from the ongoing Phase 1 ELIMINATE-B trial of PBGENE-HBV in chronic hepatitis B.
The webcast follows late-breaking biopsy data presented at the European Association for the Study of the Liver (EASL) Congress 2026 in Barcelona. A replay and a separate news release with detailed clinical data will be available on the company’s investor website after the conference embargo lifts.
iECURE (NASDAQ:DTIL) reported preliminary results from the low-dose cohort of its OTC-HOPE trial of ECUR-506 in neonatal-onset OTC deficiency.
The first treated infant showed 18 months without HAEs and stopped standard care. Across three low-dose patients, annualized HAEs fell 57% and HACs 65%, with generally well-tolerated safety in seven dosed participants.
Precision BioSciences (Nasdaq: DTIL) reported new preclinical PBGENE-DMD data at the ASGCT 2026 meeting. Early-juvenile DMD mice showed up to 3x higher skeletal and 12x higher respiratory dystrophin restoration versus late-juvenile mice, with diaphragm up to 12% and intercostals up to 30%, supporting evaluation in boys aged 2–3 years within the Phase 1/2 FUNCTION-DMD trial.
iECURE (NASDAQ:DTIL) reported preliminary data from the ongoing OTC-HOPE trial of ECUR-506 in neonatal-onset ornithine transcarbamylase deficiency, covering 7 participants across three dose cohorts as of April 20, 2026.
71% (5/7) had no hyperammonemic crises (HACs) post-treatment and the annualized HAC rate fell about 52%, from ~3.12 to ~1.49 events per year. ECUR-506 was generally well tolerated, with no infusion-related reactions or thrombotic microangiopathy and no prophylactic immunosuppression. Asymptomatic Grade 2–3 transaminitis occurred in 5 of 7 participants and was controlled with reactive immunosuppression. One death from hypoxemic respiratory failure was assessed as unrelated to ECUR-506 and linked to underlying disease complications. These early data support continued evaluation of ECUR-506’s safety and clinical activity.
Precision BioSciences (NASDAQ: DTIL) reported Q1 2026 results and operational progress, highlighting $125.8 million in cash on March 31, 2026 and advancement of two wholly owned in vivo programs: PBGENE-HBV (ongoing ELIMINATE-B trial; late-breaking EASL poster) and PBGENE-DMD (FDA IND cleared, Fast Track, first site activated).
Q1 revenue was $10.8 million; net loss was $18.4 million, or $(0.75) per share. Company expects cash runway to support key data milestones through 2028.
Precision BioSciences (Nasdaq: DTIL) said it will publish first quarter 2026 financial results and provide a business update on May 5, 2026. The company is a clinical‑stage gene editing firm using its proprietary ARCUS platform to develop in vivo therapies for high‑unmet‑need diseases.
Precision BioSciences (Nasdaq: DTIL) activated Arkansas Children’s Hospital as the first clinical trial site and opened patient screening and enrollment for PBGENE-DMD in the Phase 1/2 FUNCTION-DMD study on April 29, 2026. PBGENE-DMD targets DMD mutations between exons 45 and 55 and will assess safety, tolerability, dystrophin expression, and functional outcomes in ambulatory patients.
Arkansas Children’s is a PPMD-certified Duchenne Care Center and an MDA Care Center; additional sites are being activated to expand enrollment.
iECURE (NASDAQ:DTIL) will present preliminary clinical data for ECUR-506 in neonatal-onset ornithine transcarbamylase (OTC) deficiency at ASGCT (May 11-15, 2026) and SIMD (May 17-20, 2026).
Oral data cover the first three dose cohorts (n=7) and report a decreased rate of hyperammonemic crises. A SIMD poster shows one-year post-treatment data for the first infant who achieved a complete clinical response with sustained discontinuation of standard-of-care therapies.
Precision BioSciences (Nasdaq: DTIL) announced an oral presentation of new preclinical PBGENE-DMD data at the ASGCT 2026 Annual Meeting, May 11-15 in Boston.
The abstract reports efficacy in early-juvenile mice and builds on prior updates showing durable functional improvement in a humanized DMD mouse model. Presentation: May 14, 2026 at 8:45 a.m. ET; Presenter: Adam Michler Ph.D., DMD Research Lead; Session: Emerging molecular therapeutic strategies for muscular dystrophies.
Precision BioSciences (Nasdaq: DTIL) announced that on April 20, 2026 the Compensation Committee approved an inducement award of 7,094 restricted stock units (RSUs) for a newly hired employee under its 2021 Inducement Award Plan.
The RSUs vest in substantially equal annual installments on each of the first three anniversaries of the employee’s start date, subject to continued service.